Last reviewed · How we verify

Insulin, sulfonylurea — Competitive Intelligence Brief

Insulin, sulfonylurea (Insulin, sulfonylurea) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin + Sulfonylurea combination. Area: Diabetes.

phase 3 Insulin + Sulfonylurea combination Insulin receptor (insulin component); ATP-sensitive potassium channel (sulfonylurea component) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Insulin, sulfonylurea (Insulin, sulfonylurea) — University of Pittsburgh. This combination therapy uses insulin to provide exogenous glucose control while sulfonylureas stimulate endogenous insulin secretion from pancreatic beta cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Insulin, sulfonylurea TARGET Insulin, sulfonylurea University of Pittsburgh phase 3 Insulin + Sulfonylurea combination Insulin receptor (insulin component); ATP-sensitive potassium channel (sulfonylurea component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin + Sulfonylurea combination class)

  1. University of Pittsburgh · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Insulin, sulfonylurea — Competitive Intelligence Brief. https://druglandscape.com/ci/insulin-sulfonylurea. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: